TW202513550A - 尼拉帕尼（niraparib）鹽 - Google Patents
尼拉帕尼（niraparib）鹽 Download PDFInfo
- Publication number
- TW202513550A TW202513550A TW113130597A TW113130597A TW202513550A TW 202513550 A TW202513550 A TW 202513550A TW 113130597 A TW113130597 A TW 113130597A TW 113130597 A TW113130597 A TW 113130597A TW 202513550 A TW202513550 A TW 202513550A
- Authority
- TW
- Taiwan
- Prior art keywords
- crystalline form
- niraparib
- salt
- indazole
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740872P | 2018-10-03 | 2018-10-03 | |
| US62/740,872 | 2018-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202513550A true TW202513550A (zh) | 2025-04-01 |
Family
ID=68345029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113130597A TW202513550A (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
| TW108135909A TWI853841B (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108135909A TWI853841B (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3860981B1 (https=) |
| JP (1) | JP7472115B2 (https=) |
| KR (1) | KR20210071022A (https=) |
| CN (2) | CN113166071B (https=) |
| ES (1) | ES2967517T3 (https=) |
| TW (2) | TW202513550A (https=) |
| WO (1) | WO2020072797A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI905184B (zh) | 2020-05-08 | 2025-11-21 | 比利時商健生藥品公司 | 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌 |
| JP2024525881A (ja) | 2021-07-19 | 2024-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療 |
| CN121311226A (zh) | 2023-05-17 | 2026-01-09 | 特沙诺有限公司 | 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (https=) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| KR101653548B1 (ko) * | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| CN108201537A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
-
2019
- 2019-10-03 CN CN201980078366.1A patent/CN113166071B/zh active Active
- 2019-10-03 TW TW113130597A patent/TW202513550A/zh unknown
- 2019-10-03 EP EP19794786.4A patent/EP3860981B1/en active Active
- 2019-10-03 KR KR1020217012838A patent/KR20210071022A/ko active Pending
- 2019-10-03 ES ES19794786T patent/ES2967517T3/es active Active
- 2019-10-03 WO PCT/US2019/054534 patent/WO2020072797A1/en not_active Ceased
- 2019-10-03 CN CN202411070879.7A patent/CN118994103A/zh active Pending
- 2019-10-03 TW TW108135909A patent/TWI853841B/zh active
- 2019-10-03 JP JP2021518561A patent/JP7472115B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN118994103A (zh) | 2024-11-22 |
| TW202028181A (zh) | 2020-08-01 |
| KR20210071022A (ko) | 2021-06-15 |
| EP3860981A1 (en) | 2021-08-11 |
| EP3860981B1 (en) | 2023-11-29 |
| WO2020072797A1 (en) | 2020-04-09 |
| ES2967517T3 (es) | 2024-04-30 |
| JP7472115B2 (ja) | 2024-04-22 |
| JP2022504236A (ja) | 2022-01-13 |
| CN113166071B (zh) | 2025-03-21 |
| CN113166071A (zh) | 2021-07-23 |
| TWI853841B (zh) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6763919B2 (ja) | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 | |
| JP2024537795A (ja) | ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製 | |
| TWI853841B (zh) | 尼拉帕尼（niraparib）鹽 | |
| US12297184B2 (en) | Niraparib salts | |
| KR20250012083A (ko) | 피페리딘일-메틸-푸린 아민 d-타르타르산 염, 결정질 형태 및 의학적 질환 및 병태 치료에서의 이들의 용도 | |
| KR20240158230A (ko) | 중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도 | |
| AU2018352382A1 (en) | Compounds and methods for treating cancer | |
| CN119013018A (zh) | 包含泛素特异性加工蛋白酶1(usp1)抑制剂和化疗剂的治疗组合 | |
| TW201008923A (en) | Novel salt | |
| JP2023502969A (ja) | ＭｅｒＴＫおよびＴＹＲＯ３の二重阻害剤としてのアリールアミノピリミジンおよびその方法 | |
| AU2012223281A1 (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |
| JP2022548618A (ja) | Ｍｌｌ１阻害剤及び抗癌剤 | |
| HK40048853A (en) | Niraparib salts | |
| HK40048853B (en) | Niraparib salts | |
| HK40120176A (zh) | 尼拉帕利盐 | |
| KR102805214B1 (ko) | Mll1 억제제 및 항암제 | |
| WO2021046178A1 (en) | Compounds and methods for treating cancer | |
| WO2009110415A1 (ja) | 併用剤 | |
| TW202542127A (zh) | 激酶抑制劑之固態形式 | |
| AU2024341981A1 (en) | Parp1 inhibitors and the use in the treatment of cns diseases | |
| TW202409035A (zh) | Akr1c3依賴性kars抑制劑的晶型 | |
| TW201136935A (en) | Salts of an indazolylpyrrolotriazine | |
| WO2021046220A1 (en) | Compounds and methods for treating cancer |